Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin's Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study

被引：2

作者：

Jurczak, Wojciech ^{[1
]}

Zinzani, Pier Luigi ^{[2
]}

Gaidano, Gianluca ^{[3
]}

Goy, Andre ^{[4
]}

Provencio, Mariano ^{[5
]}

Nagy, Zsolt ^{[6
]}

Robak, Tadeusz ^{[7
]}

Maddocks, Kami J. ^{[8
]}

Buske, Christian ^{[9
]}

Ambarkhane, Sumeet ^{[10
]}

Winderlich, Mark ^{[10
]}

Dirnberger-Hertweck, Maren ^{[10
]}

Endell, Jan ^{[10
]}

Blum, Kristie A. ^{[8
]}

机构：

[1] Jagiellonian Univ, Dept Hematol, Krakow, Poland

[2] Univ Bologna, Inst Hematol, Bologna, Italy

[3] Univ Piemonte Orientale, Dept Translat Med, Novara, Italy

[4] Hackensack Univ Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

[5] Univ Hosp Puerta Hierro, Dept Med Oncol, Madrid, Spain

[6] Semmelweis Univ, First Dept Internal Med, Budapest, Hungary

[7] Med Univ Lodz, Dept Hematol, Lodz, Poland

[8] Ohio State Univ Comprehens Canc Ctr, Div Hematol, Dept Internal Med, Columbus, OH USA

[9] Univ Hosp Ulm, Inst Expt Canc Res, Comprehens Canc Ctr Ulm, Ulm, Germany

[10] MorphoSys AG, Martinsried, Germany

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.623.623

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

623

引用

页数：6

共 50 条

[1] Subgroup analyses of diffuse large B-cell lymphoma and indolent lymphoma cohorts from a phase IIa study of single-agent MOR208 in patients with relapsed or refractory non-Hodgkin's lymphoma (R-R NHL)
Buske, C.
Jurczak, W.
Zinzani, P. L.
Gaidano, G.
Goy, A.
Provencio, M.
Nagy, Z.
Robak, T.
Maddocks, K.
Ambarkhane, S.
Winderlich, M.
Endell, J.
Blum, K. A.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 72 - 72
[2] Subgroup analyses of diffuse large B-cell lymphoma (DLBCL) and indolent lymphoma cohorts from a phase Ha study of single-agent MOR208 in patients with relapsed or refractory non-Hodgkin's lymphoma (R-R NHL).
Jurczak, Wojciech
Zinzani, Pier Luigi
Gaidano, Gianluca
Goy, Andre
Provencio, Mariano
Nagy, Zsolt
Robak, Tadeusz
Maddocks, Kamij.
Buske, Christian
Ambarkhane, Sumeet Vijay
Winderlich, Mark
Endell, Jan
Blum, Kristie A.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[3] Phase IIa study of single-agent MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).
Jurczak, Wojciech
Zinzani, Pier Luigi
Goy, Andre
Provencio, Mariano
Nagy, Zsolt
Robak, Tadeusz
Maddocks, Kami J.
Buske, Christian
Korolkiewicz, Roman
Winderlich, Mark
Blum, Kristie A.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[4] SUBGROUP ANALYSES OF DIFFUSE LARGE B-CELL LYMPHOMA AND INDOLENT LYMPHOMA COHORTS FROM A PHASE IIA STUDY OF SINGLE-AGENT MOR208 IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN'S LYMPHOMA
Jurczak, W.
Zinzani, P. L.
Gaidano, G.
Goy, A.
Provencio, M.
Nagy, Z.
Robak, T.
Maddocks, K.
Buske, C.
Ambarkhane, S.
Winderlich, M.
Endell, J.
Blum, K.
HAEMATOLOGICA, 2016, 101 : 317 - 317
[5] Phase IIa Study of Single-Agent MOR208 in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Jurczak, Wojciech
Zinzani, Pier Luigi
Gaidano, Gianluca
Goy, Andre
Provencio, Mariano
Nagy, Zsolt
Robak, Tadeusz
Maddocks, Kami J.
Buske, Christian
Korolkiewicz, Roman Pawel
Striebel, Frank
Blum, Kristie
BLOOD, 2015, 126 (23)
[6] Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma
Jurczak, W.
Zinzani, P. L.
Gaidano, G.
Goy, A.
Provencio, M.
Nagy, Z.
Robak, T.
Maddocks, K.
Buske, C.
Ambarkhane, S.
Winderlich, M.
Dirnberger-Hertweck, M.
Korolkiewicz, R.
Blum, K. A.
ANNALS OF ONCOLOGY, 2018, 29 (05) : 1266 - 1272
[7] L-MIND: MOR208 COMBINED WITH LENALIDOMIDE (LEN) IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R-R DLBCL)-A SINGLE-ARM PHASE II STUDY
Maddocks, K.
Gonzalez Barca, E.
Jurczak, W.
Liberati, A. M.
Duell, J.
Nagy, Z.
Papaj-K, T.
Andre, M.
Kalakonda, N.
Dreyling, M.
Zinzani, P. L.
Ambarkhane, S.
Weirather, J.
Salles, G.
HAEMATOLOGICA, 2017, 102 : 174 - 174
[8] L-MIND: MOR208 combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R-R DLBCL) - a single-arm phase II study
Duell, J.
Gonzalez Barca, E.
Liberati, A. M.
Salles, G.
Gaidano, G.
Jurczak, W.
Nagy, Z.
Papajlk, T.
Andre, M.
Zinzani, P. L.
Kalakonda, N.
Ambarkhane, S.
Weirather, J.
Maddocks, K.
Dreyling, M.
ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 68 - 68
[9] A pilot study of combined therapy with rituximab (R) and epoch in refractory or relapsed diffuse large B-cell Non-Hodgkin's Lymphoma (NHL).
Aung, S
Krishnan, J
Lessin, L
Priebat, D
Sharma, D
Malkovska, V
BLOOD, 1999, 94 (10) : 257B - 257B
[10] L-mind: MOR208 combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large b-cell lymphoma (R-R DLBCL)-A single-arm phase II study.
Maddocks, Kami J.
Barca, Eva Gonzalez
Jurczak, Wojciech
Liberati, Anna Marina
Duell, Johannes
Nagy, Zsolt
Papajik, Tomas
Andre, Marc
Kalakonda, Nagesh
Dreyling, Martin H.
Zinzani, Pier Luigi
Ambarkhane, Sumeet Vijay
Weirather, Johannes
Salles, Gilles A.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

← 1 2 3 4 5 →